Litmys, a life sciences commercial strategy consulting firm specializing in commercial readiness and adoption analytics, and PharmaACE, a global life sciences consulting and analytics firm, announced a strategic collaboration designed to help life sciences companies make more informed development, investment, and commercialization decisions. The collaboration brings together Litmys' expertise in understanding and quantifying the factors that drive real-world product adoption and PharmaACE's advanced forecasting, commercial modeling, and analytics capabilities. By connecting these disciplines, the companies aim to help life sciences organizations develop more realistic assessments of market potential and translate those insights into stronger commercial strategies.
"Approval does not equal adoption, and a forecast is only as good as the assumptions behind it," said Harris Kaplan, Managing Partner at Litmys. "Our work focuses on understanding what will actually drive physicians, payers, and patients to embrace a new product. Combining that perspective with PharmaACE's sophisticated forecasting and analytics capabilities allows us to connect the drivers of adoption more directly to commercial expectations and help clients make better decisions while they still have time to influence the outcome."
Traditional pharmaceutical forecasts often rely heavily on clinical profiles, market size, and assumptions about future market share. Yet commercial success ultimately depends on whether physicians prescribe, payers provide access, and patients adopt new therapies. Understanding how these stakeholders influence one another, and how those interactions affect demand, is essential to building more reliable forecasts.
Litmys' proprietary RAMPx™ (Realistic Assessment of Market Potential) methodology evaluates the drivers of real-world adoption, identifying product advantages, barriers to adoption, and stakeholder willingness to change current behaviors. PharmaACE contributes sophisticated forecasting models, commercial analytics, and strategic consulting capabilities to help translate these insights into actionable market projections and business decisions.
"The strongest forecasts do more than project market share. They reflect a clear understanding of the factors that will influence whether a product is prescribed, reimbursed, and used. Our collaboration with Litmys brings additional depth to those assumptions, combining their expertise in stakeholder adoption with our forecasting and analytics capabilities to help clients make more confident commercial decisions," said Michael Devinoff, Chief Strategy Officer at PharmaACE.